The development of a yeast-based in vivo assay system provides a tool for screening inhibitors of the HCV NS3 protease, a key target for antiviral agents.
May enable NS3 inhibitor screening in research; leaves open clinical translation for HCV antivirals.
The polyprotein encoded by hepatitis C virus (HCV) genomic RNA is processed into functional proteins by both host- and virus-encoded proteases. The HCV-encoded protease NS3 is responsible for the processing of junctions NS3/4, 4A/4B, 4B/5A, and 5A/5B. This protease is believed to be essential for virus proliferation. Therefore, HCV NS3 is a good therapeutic target in developing antiviral agents against HCV. We developed an in vivo assay system suitable for screening inhibitors of protease NS3 by using an artificial yeast transcription activator and a yeast strain generated to monitor the transcription activator function.
No takes yet. Share an insight, caveat, or question.
Song et al. (1996) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: